RU2017139767A - Концентрированные терапевтические фосфолипидные композиции - Google Patents

Концентрированные терапевтические фосфолипидные композиции Download PDF

Info

Publication number
RU2017139767A
RU2017139767A RU2017139767A RU2017139767A RU2017139767A RU 2017139767 A RU2017139767 A RU 2017139767A RU 2017139767 A RU2017139767 A RU 2017139767A RU 2017139767 A RU2017139767 A RU 2017139767A RU 2017139767 A RU2017139767 A RU 2017139767A
Authority
RU
Russia
Prior art keywords
composition
phospholipids
concentration
formula
extract
Prior art date
Application number
RU2017139767A
Other languages
English (en)
Other versions
RU2755902C2 (ru
RU2017139767A3 (ru
Inventor
Фотини САМПАЛИ
Анри АРЛАН
Original Assignee
Акасти Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43921214&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2017139767(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Акасти Фарма, Инк. filed Critical Акасти Фарма, Инк.
Publication of RU2017139767A publication Critical patent/RU2017139767A/ru
Publication of RU2017139767A3 publication Critical patent/RU2017139767A3/ru
Application granted granted Critical
Publication of RU2755902C2 publication Critical patent/RU2755902C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (54)

1. Композиция, включающаяся фосфолипидные соединения Формулы I:
Figure 00000001
(I);
где R1 и R2 каждый независимо представляют собой остаток докозагексаеноевой кислоты (DHA) или эйкозапентаеновой кислоты (EPA);
каждый X независимо выбран из -CH2CH2NH3, -CH2CH2N(CH3)3 или
Figure 00000002
;
общее количество фосфолипидов в композиции находится в концентрации от 50% (мас./мас. (фосфолипиды/вся композиция)) до 99% (мас./мас. (фосфолипиды/вся композиция)); композиция дополнительно содержит свободный ЕРА и свободный DHА;
где
общее количество EPA в композиции составляет от 15 мас.% до 25 мас.%; и
общее количество DHА в композиции составляет от 10 мас.% до 15 мас.%.
2. Композиция по п. 1, отличающаяся тем, что фосфолипидные соединения Формулы I находятся в концентрации от 60%±5% (мас./мас. (фосфолипиды/вся композиция)) до 70%±5% (мас./мас. (фосфолипиды/вся композиция)).
3. Композиция по п. 2, отличающаяся тем, что фосфолипидные соединения Формулы I находятся в концентрации 66% ±5% (мас./мас. (фосфолипиды/вся композиция)).
4. Композиция по п. 1, отличающаяся тем, что соединения Формулы I находятся в концентрации более 70% (мас./мас. (фосфолипиды/вся композиция)) до 90% (мас./мас. (фосфолипиды/вся композиция)) по массе фосфолипидов от общей массы композиции.
5. Композиция по п. 4, отличающаяся тем, что фосфолипидные соединения Формулы I находятся в концентрации от 80% (мас./мас. (фосфолипиды/вся композиция)) до 90% (мас./мас. (фосфолипиды/вся композиция)).
6. Композиция по п. 5, отличающаяся тем, что фосфолипидные соединения Формулы I находятся в концентрации 90% (мас./мас. (фосфолипиды/вся композиция)).
7. Композиция по п. 1, отличающаяся тем, что концентрированный терапевтический фосфолипидный экстракт содержит одинаковое количество эйкозапентаеновой кислоты и докозагексаеноевой кислоты.
8. Композиция по п. 1, отличающаяся тем, что композиция дополнительно содержит триглицериды и где концентрация триглицеридов составляет менее чем 5% (мас./мас. (триглицериды/вся композиция)).
9. Композиция по п. 1, отличающаяся тем, что дополнительно содержит дополнительный антиоксидант.
10. Композиция по п. 9, отличающаяся тем, что дополнительный антиоксидант выбран из астаксантина, каротиноида и флавоноида.
11. Композиция по п. 10, отличающаяся тем, что дополнительный антиоксидант является каротиноидом.
12. Композиция по п. 11, отличающаяся тем, что каротиноид является про-витамином A или витамином Е.
13. Композиция по п. 1, для снижения уровней триглицеридов, циркулирующих в плазме.
14. Композиция по п. 13, дополнительно снижает концентрации ЛПНП- холестерина в плазме и повышает концентрации ЛПВП-холестерина в плазме.
15. Композиция по п. 11, отличающаяся тем, что фосфолипидные соединения включают фосфатидилэтаноламин, фосфатидилхолин, лизофосфатидилэтаноламин, N-ацил-фосфатидилэтаноламин (APE) и лизофосфатидилхолин.
16. Капсула, содержащая концентрированный терапевтический экстракт масла криля, где концентрированный терапевтический экстракт масла криля содержит фосфолипидные соединения Формулы I:
Figure 00000001
(I);
где R1 и R2 каждый независимо представляют собой остаток докозагексаеноевой кислоты (DHA) или эйкозапентаеновой кислоты (EPA);
каждый X независимо выбран из -CH2CH2NH3, -CH2CH2N(CH3)3 или
Figure 00000002
;
общее количество фосфолипидов в экстракте находится в концентрации от 50% (мас./мас. (фосфолипиды/вся композиция)) до 99% (мас./мас. (фосфолипиды/вся композиция)); и композиция дополнительно содержит свободный ЕРА и свободный DHА;
где
общее количество EPA в композиции составляет от 15 мас.% до 25 мас.%; и
общее количество DHА в композиции составляет от 10 мас.% до 15 мас.%,
экстракт пригоден для потребления человеком.
17. Капсула по п. 16, отличающаяся тем, что композиция дополнительно содержит триглицериды в концентрации менее чем 5 % (мас./мас. (триглицериды/вся композиция)).
18. Капсула по п. 16, отличающаяся тем, что фосфолипидные соединения Формулы I находятся в концентрации от 60%±5% (мас./мас. (фосфолипиды/вся композиция)) до 70%±5% (мас./мас. (фосфолипиды/вся композиция)).
19. Капсула по п. 16, отличающаяся тем, что фосфолипидные соединения Формулы I находятся в концентрации 66% ±5% (мас./мас. (фосфолипиды/вся композиция)).
20. Капсула по п. 16, отличающаяся тем, что экстракт получен из криля.
21. Использование композиции для получения фармацевтических композиций для снижения уровня триглицеридов в сыворотке крови, где композиция содержит эффективное количество концентрированного терапевтического фосфолипидного экстракта,
где:
экстракт содержит фосфолипидные соединения Формулы I:
Figure 00000001
(I);
R1 и R2 каждый независимо представляют собой остаток докозагексаеноевой кислоты (DHA) или эйкозапентаеновой кислоты (EPA);
каждый X независимо выбран из -CH2CH2NH3, -CH2CH2N(CH3)3 или
Figure 00000002
;
где общее количество фосфолипидных соединений Формулы I из экстракта находится в концентрации от 50% до 90% (мас./мас. (фосфолипиды/вся композиция));
общее количество EPA в экстракте составляет от 15 мас.% до 25 мас.%;
общее количество DHА в экстракте составляет от 10 мас.% до 15 мас.%,
и
экстракт пригоден для потребления человеком.
22. Использование по п.21, отличающееся тем, что композиция содержится в капсуле.
23. Использование по п.21, отличающееся тем, что композиция является маслом криля.
24. Использование по п.21, отличающееся тем, что экстракт дополнительно содержит триглицериды в концентрации менее чем 5 % (мас./мас. (триглицериды/вся композиция)).
25. Использование по п.21, отличающееся тем, что фосфолипидные соединения Формулы I находятся в концентрации от 60%±5% (мас./мас. (фосфолипиды/вся композиция)) до 70%±5% (мас./мас. (фосфолипиды/вся композиция)).
26. Использование по п.21, отличающаяся тем, что фосфолипидные соединения Формулы I находятся в концентрации 66% ±5% (мас./мас. (фосфолипиды/вся композиция)).
RU2017139767A 2009-10-29 2010-10-29 Концентрированные терапевтические фосфолипидные композиции RU2755902C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25610609P 2009-10-29 2009-10-29
US61/256,106 2009-10-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2012122059A Division RU2642653C2 (ru) 2009-10-29 2010-10-29 Концентрированные терапевтические фосфолипидные композиции

Publications (3)

Publication Number Publication Date
RU2017139767A true RU2017139767A (ru) 2019-02-12
RU2017139767A3 RU2017139767A3 (ru) 2020-02-28
RU2755902C2 RU2755902C2 (ru) 2021-09-22

Family

ID=43921214

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017139767A RU2755902C2 (ru) 2009-10-29 2010-10-29 Концентрированные терапевтические фосфолипидные композиции
RU2012122059A RU2642653C2 (ru) 2009-10-29 2010-10-29 Концентрированные терапевтические фосфолипидные композиции

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012122059A RU2642653C2 (ru) 2009-10-29 2010-10-29 Концентрированные терапевтические фосфолипидные композиции

Country Status (24)

Country Link
US (4) US8586567B2 (ru)
EP (2) EP3335713B1 (ru)
JP (3) JP5827625B2 (ru)
KR (1) KR101788342B1 (ru)
CN (2) CN104434935B (ru)
AR (1) AR078850A1 (ru)
AU (1) AU2010312238C1 (ru)
BR (1) BR112012011478B1 (ru)
CA (2) CA2779162C (ru)
CL (1) CL2012001124A1 (ru)
DK (1) DK2493478T3 (ru)
ES (1) ES2663714T3 (ru)
HK (1) HK1208800A1 (ru)
IL (2) IL219457B (ru)
MX (2) MX2012004977A (ru)
NO (1) NO2493478T3 (ru)
NZ (1) NZ600167A (ru)
PT (1) PT2493478T (ru)
RU (2) RU2755902C2 (ru)
SA (1) SA110310813B1 (ru)
TW (2) TWI494110B (ru)
UY (1) UY32989A (ru)
WO (1) WO2011050474A1 (ru)
ZA (1) ZA201203367B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011873A2 (en) 2001-07-27 2003-02-13 Neptune Technologies & Bioressources Inc. Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
ES2415684T3 (es) 2007-03-28 2013-07-26 Aker Biomarine As Composiciones de aceite de kril biológicamente eficaces
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US8586567B2 (en) * 2009-10-29 2013-11-19 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
WO2011091160A1 (en) * 2010-01-20 2011-07-28 Henry Wu Custom-formulated phospholipid microbubbles and methods and uses thereof
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
US9763897B2 (en) 2010-04-30 2017-09-19 U.S. Nutraceuticals, LLC Therapeutic astaxanthin and phospholipid composition and associated method
US8952000B2 (en) * 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
CN102210764B (zh) * 2011-05-30 2013-04-17 陕西师范大学 甜杏仁油在制备治疗心肌缺血再灌注损伤药物中应用
WO2013033618A1 (en) 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content
RU2464986C1 (ru) * 2011-11-09 2012-10-27 Вячеслав Анатольевич Игнатьев Способ проф. игнатьева снижения массы тела человека
WO2013149384A1 (en) * 2012-04-05 2013-10-10 Nippon Suisan Kaisha, Ltd. Brain atrophy prevention agent
AU2013277441B2 (en) * 2012-06-17 2017-07-06 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
KR101660195B1 (ko) 2012-07-19 2016-09-26 유.에스. 뉴트라수티칼스, 엘.엘.씨. 크릴 오일과 반응한 아스타잔틴 조성물 및 관련 방법
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
EP2968246A4 (en) * 2013-03-13 2016-08-03 Matinas Biopharma Inc OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
US9295683B2 (en) * 2013-03-14 2016-03-29 Aker Biomarine Antarctic As Omega-3 phospholipid supplements for improved brain maturity
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
GB201402450D0 (en) * 2014-02-12 2014-03-26 Aker Biomarine As Liquid phospholipid-containing compositions for preperation of pharmaceuticals
GB201402457D0 (en) * 2014-02-12 2014-03-26 Aker Biomarine As Capsules containing high doses of phospholipids
WO2015142999A1 (en) * 2014-03-19 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and reduce low density lipoprotein (ldl) per-oxidation in humans using algae based oils and astaxanthin
GB201407345D0 (en) 2014-04-25 2014-06-11 Aker Biomarine As Krill Phospholipid compositions
US11147841B2 (en) 2014-12-19 2021-10-19 Aker Biomarine Antarctic As Enhanced omega-3 formulations
NZ735362A (en) * 2015-02-11 2019-01-25 Aker Biomarine Antarctic As Lipid compositions
DE102015106095A1 (de) * 2015-04-21 2016-10-27 K. D. Pharma Bexbach Gmbh Neue Anwendung von Omega-3-Fettsäure(n)
US10328105B2 (en) * 2015-05-27 2019-06-25 Rimfrost Technologies As Flowable concentrated phospholipid krill oil composition
US20180243345A1 (en) * 2015-08-20 2018-08-30 Avoca, Inc. Method for increasing muscle growth using krill extract
WO2017211780A1 (en) * 2016-06-06 2017-12-14 Ludwig-Maximilians-Universitaet Muenchen Kaempferol for the treatment of cardiac diseases
CN106336433B (zh) * 2016-08-22 2018-04-27 浙江大学 一种拟南芥活性组分提取物及其制备方法和应用
EP3727404B1 (en) 2017-12-22 2023-08-30 Pharmalink International Limited Compositions comprising mussel lipid extract and krill oil, and their medical applications
CN109198628A (zh) * 2018-10-10 2019-01-15 陶燃 一种治疗抑郁症及焦虑症的组合物及其用途
US20220125857A1 (en) * 2019-02-12 2022-04-28 Acasti Pharma Inc. Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids
WO2020177728A1 (zh) 2019-03-05 2020-09-10 四川国为制药有限公司 脂肪酸组合物及其应用
EP3958973A4 (en) * 2019-04-26 2023-06-07 Cytosolve, Inc. COMPOSITIONS TO IMPROVE BRAIN HEALTH AND MEMORY
WO2021138742A1 (en) * 2020-01-10 2021-07-15 Acasti Pharma Inc. Composition that promote pro-resolving mediators
WO2022140580A1 (en) * 2020-12-24 2022-06-30 Orn Almarsson Xanthophyll derivatives
AU2022408040A1 (en) * 2021-12-06 2024-05-30 The Children's Medical Center Corporation Compositions comprising modified phospholipids and uses thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT331374B (de) 1972-12-22 1976-08-25 Studiengesellschaft Kohle Mbh Verfahren zur gewinnung von fetten und olen aus pflanzlichen und tierischen produkten
JPS5248191B2 (ru) 1974-12-27 1977-12-08
JPS53112195A (en) 1977-03-10 1978-09-30 Nippon Paint Co Ltd Method for producing food for fish
CA1098900A (en) 1977-12-14 1981-04-07 Sergei V. Rogozhin Method for the processing of krill to produce protein, lipids and chitin
JPS6029463B2 (ja) 1978-08-09 1985-07-10 味の素株式会社 オキアミエキスの品質改善法
NO147365C (no) 1980-11-27 1983-03-30 Jan Raa Fremgangsmaate til fremstilling av astaxanthin i en form som er egnet for innlemmelse i for for oppdrettfisk.
DE3379589D1 (en) 1982-10-25 1989-05-18 Hellgren Lars G I Enzyme composition for cleaning, the use thereof and preparation of the composition
JPS59196032A (ja) 1983-04-23 1984-11-07 Fumio Nishikawa オキアミの変性防止及び鮮度保持の方法
JPS603507A (ja) 1983-06-21 1985-01-09 Hitachi Ltd 配線パタ−ン検出装置
JPS60153779A (ja) 1984-01-24 1985-08-13 Hohnen Oil Co Ltd 栄養補助食品
JPS6035057A (ja) 1984-06-27 1985-02-22 San Ei Chem Ind Ltd 黄橙色ないし赤橙色色素の製法
US5006281A (en) 1985-03-26 1991-04-09 Century Laboratories, Inc. Process for the production of a marine animal oil
IT1215291B (it) 1985-07-17 1990-01-31 Inverni Della Beffa Spa Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche.
IT1187687B (it) 1985-07-17 1987-12-23 Inverni Della Beffa Spa Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
JPS6323819A (ja) 1986-07-16 1988-02-01 Kao Corp 血小板凝集抑制剤
IT1201149B (it) 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
IT1201151B (it) 1987-01-14 1989-01-27 Indena Spa Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
JPS63295698A (ja) 1987-05-27 1988-12-02 Showa Denko Kk α−リノレン酸の分離精製法
US4915876A (en) 1987-07-20 1990-04-10 General Mills, Inc. Process for the deodorization and stabilization of polyunsaturated oils
JPS6450890A (en) 1987-08-20 1989-02-27 Nippon Oils & Fats Co Ltd Production of docosahexaenoic acid-containing phosphatidyl choline
JPH02167055A (ja) 1988-12-19 1990-06-27 Seiji Nojima 機能性練製品
JP2909508B2 (ja) * 1989-02-14 1999-06-23 マルハ株式会社 オキアミリン脂質の分取方法
JP2963152B2 (ja) 1990-06-28 1999-10-12 クロリンエンジニアズ株式会社 オキアミからの色素の抽出分離方法
JP3092180B2 (ja) 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
ATE89599T1 (de) 1991-04-02 1993-06-15 Vandemoortele Int Nv Verfahren zur kontinuierlichen entschleimung eines glyceridoeles.
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
DE4219360C2 (de) 1992-06-12 1994-07-28 Milupa Ag Verfahren zur Gewinnung von Lipiden mit einem hohen Anteil von langkettig-hochungesättigten Fettsäuren
GB9301629D0 (en) 1993-01-27 1993-03-17 Scotia Holdings Plc Formulations containing unsaturated fatty acids
JP2558050B2 (ja) 1993-02-18 1996-11-27 イセ食品株式会社 鶏用飼料
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
JPH08198754A (ja) 1995-01-23 1996-08-06 Yakult Honsha Co Ltd 脳機能改善剤
ES2088750B1 (es) 1995-01-24 1997-03-01 Cruz Bartolome A Grillo Procedimiento para la preparacion y conservacion de un suplemento alimenticio natural a base del crustaceo euphasia superba del antartico aplicable para el consumo humano.
JP3398248B2 (ja) 1995-03-16 2003-04-21 新日本石油株式会社 キサントフィル化合物の精製方法
JPH08302382A (ja) 1995-05-09 1996-11-19 Nippon Synthetic Chem Ind Co Ltd:The 魚油の精製法
GB9510636D0 (en) 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
JPH09124470A (ja) 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物
JP2815562B2 (ja) 1995-11-13 1998-10-27 植田製油株式会社 高度不飽和脂肪酸含有油脂の精製方法
WO1997039759A2 (en) 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
JPH10155459A (ja) * 1996-11-27 1998-06-16 Suntory Ltd アスタキサンチン含有飲食物
US6055936A (en) 1997-01-21 2000-05-02 Collin; Peter Donald Sea cucumber carotenoid lipid fractions and process
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
DE69933027T2 (de) 1998-06-05 2007-03-08 Merck Patent Gmbh Meeresöl mit weniger Verunreinigungen
JP2000060432A (ja) * 1998-08-27 2000-02-29 Nippon Kagaku Shiryo Kk 高度不飽和脂肪酸を多量に含有する高品質リン脂質の製造法
CA2251265A1 (en) * 1998-10-21 2000-04-21 Universite De Sherbrooke Process for lipid extraction of aquatic animal tissues producing a dehydrated residue
US20030113432A1 (en) 1998-11-02 2003-06-19 Nippon Suisan Kaisha, Ltd. Process for making dried powdery and granular krill
CA2260397A1 (en) 1999-01-29 2000-07-29 Atlantis Marine Inc. Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
CA2290885A1 (fr) 1999-12-02 2001-06-02 Universite De Sherbrooke Methode pour la transformation des tissus du loup marin
KR100344907B1 (ko) 1999-12-13 2002-07-20 네오메가(주) 정제 어유 제조방법
KR20020037140A (ko) 2000-11-13 2002-05-18 권승룡 지질 저하 활성을 갖는 플라보노이드를 포함하는 터몹시스알터니플로라 추출물 및 이를 유효 성분으로 하는 약학적조성물
CA2325377A1 (en) 2000-11-14 2002-05-14 Adrien R. Beaudoin Process for the extraction of lipids from bird's skin and fat tissues
IL142952A (en) 2001-05-03 2005-12-18 Enzmotec Ltd Process for enzyme-catalyzed production of 1,2 diacylated phospholipids
WO2002092540A1 (en) 2001-05-14 2002-11-21 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms
ATE419858T1 (de) 2001-06-18 2009-01-15 Neptune Technologies & Bioress Krillextrakte zur prävention und/oder behandlung von herz-kreislauf-erkrankungen
WO2003011873A2 (en) * 2001-07-27 2003-02-13 Neptune Technologies & Bioressources Inc. Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US7488503B1 (en) 2003-03-31 2009-02-10 Mccormick & Company, Inc. Encapsulation compositions and processes for preparing the same
US20060217445A1 (en) 2003-07-25 2006-09-28 Chew Boon P Natural astaxanthin extract reduces dna oxidation
CN102309573B (zh) 2003-09-12 2013-11-20 捷通国际有限公司 细胞因子调节剂及相关用法
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
AU2005209480B2 (en) 2004-01-30 2010-09-02 Bionovate Limited Solvent extraction of lipids such as essential fatty acids
TW200811280A (en) 2006-04-20 2008-03-01 Owen John Catchpole Product and process
WO2008149177A2 (en) 2006-05-05 2008-12-11 Natural Asa Marine lipid compositions and uses thereof
US20080021000A1 (en) 2006-07-19 2008-01-24 Su Chen Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
KR20090085682A (ko) * 2006-11-16 2009-08-07 프로노바 바이오파마 노르지 에이에스 크릴로부터 오메가-3가 풍부한 해양 인지질을 제조하는 방법
ES2415684T3 (es) 2007-03-28 2013-07-26 Aker Biomarine As Composiciones de aceite de kril biológicamente eficaces
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US20090118227A1 (en) 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
EP2085089A1 (en) * 2008-02-01 2009-08-05 KTB-Tumorforschungs GmbH Phospholipids Containing omega-3-Fatty Acids for the Treatment of Overweight, Obesity and Addictive Behavior
WO2009132463A1 (en) 2008-05-02 2009-11-05 Neptune Technologies & Bioressources Inc. New deodorization method and organoleptic improvement of marine oil extracts
CN101333229A (zh) 2008-05-10 2008-12-31 中国海洋大学 一种提取富含二十碳五烯酸及二十二碳六烯酸磷脂的方法
NZ595204A (en) 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
KR20120059447A (ko) * 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
US8586567B2 (en) 2009-10-29 2013-11-19 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
WO2011137160A2 (en) * 2010-04-30 2011-11-03 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans

Also Published As

Publication number Publication date
AU2010312238A1 (en) 2012-06-14
AU2010312238B2 (en) 2016-08-11
NO2493478T3 (ru) 2018-07-21
CA2989078A1 (en) 2011-05-05
IL262567A (en) 2018-12-31
CN102753182A (zh) 2012-10-24
AU2010312238C1 (en) 2017-03-23
US20160375043A1 (en) 2016-12-29
US20110160161A1 (en) 2011-06-30
RU2642653C2 (ru) 2018-01-25
JP2013508431A (ja) 2013-03-07
TWI573591B (zh) 2017-03-11
CA2779162C (en) 2018-02-06
EP2493478A4 (en) 2013-02-27
US20140141074A1 (en) 2014-05-22
RU2755902C2 (ru) 2021-09-22
US20190060332A1 (en) 2019-02-28
TWI494110B (zh) 2015-08-01
HK1208800A1 (en) 2016-03-18
CA2779162A1 (en) 2011-05-05
EP2493478B1 (en) 2018-02-21
NZ600167A (en) 2014-06-27
UY32989A (es) 2011-04-29
US10617702B2 (en) 2020-04-14
RU2012122059A (ru) 2013-12-10
EP3335713A1 (en) 2018-06-20
EP2493478B8 (en) 2018-03-28
AR078850A1 (es) 2011-12-07
MX366175B (es) 2019-07-01
JP6346121B2 (ja) 2018-06-20
JP2018138612A (ja) 2018-09-06
ZA201203367B (en) 2013-08-28
TW201603813A (zh) 2016-02-01
CL2012001124A1 (es) 2013-03-15
IL219457A0 (en) 2012-06-28
ES2663714T3 (es) 2018-04-16
KR101788342B1 (ko) 2017-10-19
CA2989078C (en) 2020-06-30
IL262567B (en) 2021-08-31
CN104434935A (zh) 2015-03-25
US9475830B2 (en) 2016-10-25
US10130644B2 (en) 2018-11-20
MX2012004977A (es) 2012-11-06
JP2015147793A (ja) 2015-08-20
CN104434935B (zh) 2019-07-16
EP2493478A1 (en) 2012-09-05
IL219457B (en) 2019-05-30
TW201119658A (en) 2011-06-16
RU2017139767A3 (ru) 2020-02-28
CN102753182B (zh) 2014-10-29
DK2493478T3 (en) 2018-03-26
SA110310813B1 (ar) 2014-06-17
BR112012011478B1 (pt) 2021-12-21
WO2011050474A1 (en) 2011-05-05
PT2493478T (pt) 2018-04-03
EP3335713B1 (en) 2022-08-31
JP5827625B2 (ja) 2015-12-02
BR112012011478A2 (pt) 2018-04-03
KR20130006589A (ko) 2013-01-17
US8586567B2 (en) 2013-11-19

Similar Documents

Publication Publication Date Title
RU2017139767A (ru) Концентрированные терапевтические фосфолипидные композиции
ES2415684T3 (es) Composiciones de aceite de kril biológicamente eficaces
ES2561482T3 (es) Monoglicéridos de ácido graso poliinsaturado, derivados, y sus usos
AU2013319911B2 (en) Omega-3 phospholipid supplements for females
WO2013153071A3 (en) A nutritional composition
ES2859753T3 (es) Trastornos que implican la oxidación de PUFA
US20150164841A1 (en) Concentration of omega-3 polyunsaturated fatty acids in krill oil
US20070122452A1 (en) Fat composition
WO2006111633A3 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
ES2889874T3 (es) Tratamiento de neuropatía óptica y reducción del estrés oxidativo inducido por esteroides con sustancias polinsaturadas estabilizadas
MY143962A (en) Oil or fat compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
JP2014517028A5 (ru)
US20230310470A1 (en) Intelligent delivery of ingested and absorbed molecules
WO2011137160A3 (en) Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
JP2020121972A (ja) Ｎａｆｌｄ治療用組成物
AU2017201340B2 (en) Bio effective krill oil compositions
Hiratsuka et al. Effect of dietary docosahexaenoic acid connecting phospholipids on the lipid peroxidation of the brain in mice
DE502004008949D1 (de) Physiologisch aktive zusammensetzung auf phosphatidylserin-basis
EP2952209B1 (en) Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration
JP6824506B2 (ja) 脂質組成物
AU2011213836B2 (en) Bioeffective krill oil compositions
Zhang Omega-3 phospholipids
RU2181757C2 (ru) Состав для стабилизации липидов
JP6519875B2 (ja) 改良された魚油ベースのオメガ３補助食品
RU2566983C1 (ru) Состав для стабилизации липидов к окислению

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200901

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20210603